FDA paper alert! Dive into the future of healthcare with the FDA’s latest paper on “Artificial Intelligence & Medical Products.”
Artificial intelligence has the potential to transform medical product development, enhancing patient care, and empowering healthcare professionals.
The Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH), and Office of Combination Products (OCP) are joining forces in this paper to ensure public health is protected while promoting ethical innovation.
Interested in our AI expertise within the FDA regulation context? Discover more at medicaldevices.ipn.pt